|
|
 |
|
Viewing report
|
|
|
|
The Future of the Biodefense Industry: Regulation, Funding Opportunities & Company Profiles
Business Insights, Sep 2009, Pages: 183
The major contemporary bioterrorist event which has opened up programs of research and development (R&D) in pharmaceutical countermeasures and treatments was the anthrax mail attacks which occurred only weeks after the 9/11 atrocities, in October 2001. The mailings killed five people and exposed hundreds more – with thousands of US citizens seeking prophylactic antibiotics. Since then the biodefense industry has grown massively, with the US releasing around $50bn in biodefence funding in 2001-2009. Other international bodies, such as the EU, have also increased their vigilance and research efforts.
This report sets out to describe and analyze the work of the biodefense industry in terms of past, present and future pharmaceutical research, development and production to counter or treat diseases caused by biological attack. It also will describe government policies and initiatives in several countries which have spurred research and production in pharmaceutical countermeasures and treatments for such diseases and will examine the various factors which influence those policies and the market, including current and future threats and how the industry is responding to new discoveries.
Scope of this report
- Analysis of government funding levels in the US and Europe and information on current grants available for biodefense research.
- Estimation of biodefense in the US for 2010 and forecast figures to 2012.
- In-depth analysis of the major biodefense firms operating in the US, Europe, Australia and Canada as well as well as those operating in emerging markets such as China, India and Israel.
- Analysis of the major threat areas in the biodefense market including - anthrax, plague, tularemia, small pox viral hemorrhagic fevers, botulism, ricin, staphylococcal enterotoxins, brucella, glanders, melioidosis and Q fever.
Key findings from this report
- The US is driving the industry and total biodefense funding between 2001-2009 reached $49.6bn. However, growth is set to slow significantly in the coming years as all Project BioShield funding has now released.
- However, a single serious bioterrorist incident in the US could spur another round of government spending as happened after the 2001 anthrax attacks. Recent threats such as pandemic swine flu are also forcing governments to consider the creation of large stockpiles of medical countermeasure.
- The current economic crisis could be especially serious for the biodefense industry. As many of the active participants are small-scale and reliant on outside funding to maintain operations, reduced credit options could force them out of business
Key issues
- Since 2001 US funding for Biodefense has reached $49.6bn. The peak year for spending was 2005, due to a large dissemination of funds from Project BioShield, however 2009 was also witnessed strong investment.
- In 2010, Business Insights estimates that total biodefense funding in the US will reach $5,932mn. If you were to take BioShield funding out of the figures for 2009, then 2010 represented growth of 1.4% (year-on-year), a reversal of the trend seen between 2006-2008.
- There have only been a small number of bioterrorist incidents in the past thirty years, with the number of fatalities remaining limited. But due in part to the psychological fear created by these weapons, the US military, in particular, has invested heavily in preparing vaccines and therapeutics.
- The rarity of bioterrorist attacks, due to the extreme difficulty in weaponizing and delivering biological agents, has caused numerous scientific groups to criticize the current high spending levels on research into medical counter measures.
Use this report to:
- What are the major trends driving the biodefense market?
- What is the current state of R&D in the biodefense market?
- How has the regulatory pathway changed in recent years, and how is this effecting industry development?
- What are the current funding levels for biodefense and what is the forecast 2010-2012?
- Which product areas provide the greatest opportunity for future development?
Customers who bought this item also bought
Market Opportunities in Biodefense Research: Trends & Forecasts
42nd ICAAC 2002 - Biodefense and Emerging Infections
Human Vaccines - Global Strategic Business Report
Francisella Tularensis: Biology, Pathogenicity, Epidemiology, and Biodefense
Bioterrorism - Global Strategic Business Report
Veterinary Vaccines - Global Strategic Business Report
Human Vaccines - Global Market Opportunities
Veterinary Vaccines - A World Market Analysis
Vaccines Market Insight: Products, Pipelines & Market Outlook
Cancer Therapeutics Markets
Infectious Diseases Vaccine Market Overview: Key Companies & Strategies - In Times of Crisis, Big Pharma turns to Vaccines
Pipeline And Commercial Insight: Influenza Vaccines - Pandemic Threat Revitalizes The Sector
|
|
|
|
